ReviewCancer pathogenesis and therapy2024

Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis.

Lijuan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.